Clinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
NCT02682511 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
- Lead sponsor
- Cumberland Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 31, 2017
- Completion date
- September 30, 2026
- Enrollment
- 34 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune diseases, connective tissue diseases, pathologic processes, scleroderma, diffuse, scleroderma, limited, scleroderma, systemic, sclerosis, progressive systemic, skin diseases